Restoring function in major depressive disorder: A systematic review

Journal of Affective Disorders

Volumn 215, Issue , 2017, Pages 299-313

  Sheehan, David V ^a   Nakagome, Kazuyuki ^b   Asami, Yuko ^c   Pappadopulos, Elizabeth A ^c   Boucher, Matthieu ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^c PFIZER INC   (United States)

^d Pfizer Canada Inc Kirkland   (Canada)

Author keywords

Functional Impairment; Functional Remission; Major Depressive Disorder; Quality of Life; Social Impairment; Work Performance

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ABSENTEEISM; COGNITION; COGNITIVE BEHAVIORAL THERAPY; CONVALESCENCE; DISEASE SEVERITY; ECONOMIC ASPECT; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HUMAN; JOB PERFORMANCE; MAJOR DEPRESSION; MENTAL PATIENT; PRESENTEEISM; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; QUALITATIVE ANALYSIS; QUALITY OF LIFE; REVIEW; SHEEHAN DISABILITY SCALE; SOCIAL INTERACTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; WORKPLACE; DEPRESSIVE DISORDER, MAJOR; META ANALYSIS; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; QUALITY OF LIFE; RECOVERY OF FUNCTION;

EID: 85016285119     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2017.02.029     Document Type: Review

References (113)

1. American Psychiatric Association, Major Depressive Disorder, Diagnostic and Statistical Manual of Mental Disorders, 5th ed., 2013, American Psychiatric Association, Washington, DC, 160–168.
2. Asami, Y., Goren, A., Okumura, Y., Work productivity loss with depression, diagnosed and undiagnosed, among workers in an Internet-based survey conducted in Japan. J. Occup. Environ. Med 57 (2015), 105–110.
3. Asnis, G.M., Bose, A., Gommoll, C.P., Chen, C., Greenberg, W.M., Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 74 (2013), 242–248.
4. Bakish, D., Bose, A., Gommoll, C., Chen, C., Nunez, R., Greenberg, W.M., Liebowitz, M., Khan, A., Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J. Psychiatry Neurosci. 39 (2014), 40–49.
5. Bech, P., Social functioning: should it become an endpoint in trials of antidepressants?. CNS Drugs 19 (2005), 313–324.
6. Beck, A., Crain, A.L., Solberg, L.I., Unutzer, J., Glasgow, R.E., Maciosek, M.V., Whitebird, R., Severity of depression and magnitude of productivity loss. Ann. Fam. Med. 9 (2011), 305–311.
7. Beck, A., Crain, L.A., Solberg, L.I., Unutzer, J., Maciosek, M.V., Whitebird, R.R., Rossom, R.C., The effect of depression treatment on work productivity. Am. J. Manag. Care 20 (2014), e294–e301.
8. Bijl, R.V., Ravelli, A., Current and residual functional disability associated with psychopathology: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol. Med. 30 (2000), 657–668.
9. Bloom, D.E., Cafiero, E.T., Jane-Llopis, E., Abrahams-Gessel, S., Bloom, L.R., Fathima, S., Feigl, A.B., Gaziano, T., Mowafi, M., Pandya, A., Prettner, K., Rosenberg, L., Seligman, B., Stein, A., Weinstein, C., The Global Economic Burden of Non-communicable Diseases. 2011, World Economic Forum, Geneva, Switzerland.
10. Bosc, M., Dubini, A., Polin, V., Development and validation of a social functioning scale, the social Adaptation Self-evaluation scale. Eur. Neuropsychopharmacol. 7:Suppl 1 (1997), S57–S70.
11. Boulenger, J.P., Loft, H., Olsen, C.K., Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int. Clin. Psychopharmacol. 29 (2014), 138–149.
12. Burcusa, S.L., Iacono, W.G., Risk for recurrence in depression. Clin. Psychol. Rev. 27 (2007), 959–985.
13. Carrasco, J.L., Kornstein, S.G., McIntyre, R.S., Fayyad, R., Prieto, R., Salas, M., Mackell, J., Boucher, M., An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Int. Clin. Psychopharmacol. 31 (2016), 134–146.
14. Citrome, L., Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. Int J. Clin. Pr. 67 (2013), 1089–1104.
15. Demyttenaere, K., Andersen, H.F., Reines, E.H., Impact of escitalopram treatment on quality of life enjoyment and satisfaction questionnaire scores in major depressive disorder and generalized anxiety disorder. Int. Clin. Psychopharmacol. 23 (2008), 276–286.
16. Dennehy, E.B., Marangell, L.B., Martinez, J., Balasubramani, G.K., Wisniewski, S.R., Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR*D. J. Psychiatr. Pr. 20 (2014), 178–187.
17. Detke, M.J., Wiltse, C.G., Mallinckrodt, C.H., McNamara, R.K., Demitrack, M.A., Bitter, I., Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol. 14 (2004), 457–470.
18. Dubini, A., Bosc, M., Polin, V., Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J. Psychopharmacol. 11 (1997), S17–S23.
19. Dunlop, B.W., Reddy, S., Yang, L., Lubaczewski, S., Focht, K., Guico-Pabia, C.J., Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J. Clin. Psychopharmacol. 31 (2011), 569–576.
20. Endicott, J., Dorries, K.M., Functional outcomes in MDD: established and emerging assessment tools. Am. J. Manag. Care 15 (2009), S328–S334.
21. Endicott, J., Nee, J., Harrison, W., Blumenthal, R., Quality of life enjoyment and satisfaction Questionnaire: a new measure. Psychopharmacol. Bull. 29 (1993), 321–326.
22. Endicott, J., Lam, R.W., Hsu, M.A., Fayyad, R., Boucher, M., Guico-Pabia, C.J., Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder. J. Affect. Disord. 166 (2014), 307–314.
23. Evans, V.C., Iverson, G.L., Yatham, L.N., Lam, R.W., The relationship between neurocognitive and psychosocial functioning in major depressive disorder: a systematic review. J. Clin. Psychiatry 75 (2014), 1359–1370.
24. Ferguson, J.M., Wesnes, K.A., Schwartz, G.E., Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int. Clin. Psychopharmacol. 18 (2003), 9–14.
25. Finkelstein, S.N., Berndt, E.R., Greenberg, P.E., Parsley, R.A., Russell, J.M., Keller, M.B., Improvement in subjective work performance after treatment of chronic depression: some preliminary results. chronic depression study group. Psychopharmacol. Bull. 32 (1996), 33–40.
26. Florea, I., Danchenko, N., Brignone, M., Loft, H., Rive, B., Abetz-Webb, L., The effect of vortioxetine on health-related quality of life in patients with major depressive disorder. Clin. Ther., 37(2309–2323), 2015, e2306.
27. Gommoll, C.P., Greenberg, W.M., Chen, C., A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder. J. Drug. Assess. 3 (2014), 10–19.
28. Gorenstein, C., Andrade, L., Moreno, R.A., Artes, R., Social adjustment in depressed patients treated with venlafaxine and amitriptyline. Int. Clin. Psychopharmacol. 17 (2002), 171–175.
29. Greden, J.F., Workplace depression: personalize, partner, or pay the price. Am. J. Psychiatry 170 (2013), 578–581.
30. Greer, T.L., Kurian, B.T., Trivedi, M.H., Defining and measuring functional recovery from depression. CNS Drugs 24 (2010), 267–284.
31. Greer, T.L., Sunderajan, P., Grannemann, B.D., Kurian, B.T., Trivedi, M.H., Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction?. Depress Res. Treat., 2014, 2014, 627863.
32. Guico-Pabia, C.J., Fayyad, R.S., Soares, C.N., Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis. Int. Clin. Psychopharmacol. 27 (2012), 1–7.
33. Herrera-Guzman, I., Gudayol-Ferre, E., Herrera-Guzman, D., Guardia-Olmos, J., Hinojosa-Calvo, E., Herrera-Abarca, J.E., Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J. Psychiatr. Res 43 (2009), 855–863.
34. Herrera-Guzman, I., Herrera-Abarca, J.E., Gudayol-Ferre, E., Herrera-Guzman, D., Gomez-Carbajal, L., Pena-Olvira, M., Villuendas-Gonzalez, E., Joan, G.O., Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res. 177 (2010), 323–329.
35. Hewett, K., Chrzanowski, W., Schmitz, M., Savela, A., Milanova, V., Gee, M., Krishen, A., Millen, L., Leary, M.O., Modell, J., Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J. Psychopharmacol. 23 (2009), 531–538.
36. Hewett, K., Gee, M.D., Krishen, A., Wunderlich, H.P., Le, C.A., Evoniuk, G., Modell, J.G., Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J. Psychopharmacol. 24 (2010), 1209–1216.
37. Hirschfeld, R.M., Russell, J.M., Delgado, P.L., Fawcett, J., Friedman, R.A., Harrison, W.M., Koran, L.M., Miller, I.W., Thase, M.E., Howland, R.H., Connolly, M.A., Miceli, R.J., Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J. Clin. Psychiatry 59 (1998), 669–675.
38. IsHak, W.W., Greenberg, J.M., Cohen, R.M., Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). J. Affect. Disord. 151 (2013), 59–65.
39. Jaeger, J., Berns, S.M., Czobor, P., The multidimensional scale of independent functioning: a new instrument for measuring functional disability in psychiatric populations. Schizophr. Bull. 29 (2003), 153–168.
40. Jaeger, J., Berns, S., Uzelac, S., Davis-Conway, S., Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 145 (2006), 39–48.
41. Judd, L.L., Akiskal, H.S., Zeller, P.J., Paulus, M., Leon, A.C., Maser, J.D., Endicott, J., Coryell, W., Kunovac, J.L., Mueller, T.I., Rice, J.P., Keller, M.B., Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch. Gen. Psychiatry 57 (2000), 375–380.
42. Judd, L.L., Schettler, P.J., Solomon, D.A., Maser, J.D., Coryell, W., Endicott, J., Akiskal, H.S., Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J. Affect. Disord. 108 (2008), 49–58.
43. Keefe, R.S., McClintock, S.M., Roth, R.M., Doraiswamy, P.M., Tiger, S., Madhoo, M., Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. J. Clin. Psychiatry 75 (2014), 864–876.
44. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., Rush, A.J., Walters, E.E., Wang, P.S., The epidemiology of major depressive disorder: results from the National Comorbidity survey replication (NCS-R). JAMA 289 (2003), 3095–3105.
45. Kessler, R.C., Ames, M., Hymel, P.A., Loeppke, R., McKenas, D.K., Richling, D.E., Stang, P.E., Ustun, T.B., Using the world health organization health and work performance Questionnaire (HPQ) to evaluate the indirect workplace costs of illness. J. Occup. Environ. Med 46 (2004), S23–S37.
46. Kessler, R.C., Akiskal, H.S., Ames, M., Birnbaum, H., Greenberg, P., Hirschfeld, R.M., Jin, R., Merikangas, K.R., Simon, G.E., Wang, P.S., Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry 163 (2006), 1561–1568.
47. Kessler, R.C., Heeringa, S., Lakoma, M.D., Petukhova, M., Rupp, A.E., Schoenbaum, M., Wang, P.S., Zaslavsky, A.M., Individual and societal effects of mental disorders on earnings in the United States: results from the national comorbidity survey replication. Am. J. Psychiatry 165 (2008), 703–711.
48. Lam, R.W., Filteau, M.J., Milev, R., Clinical effectiveness: the importance of psychosocial functioning outcomes. J. Affect. Disord. 132:Suppl 1 (2011), S9–S13.
49. Lam, R.W., Michalak, E.E., Bond, D.J., Tam, E.M., Axler, A., Yatham, L.N., Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning?. Depress Res Treat., 2012, 2012, 630206.
50. Lam, R.W., Endicott, J., Hsu, M.A., Fayyad, R., Guico-Pabia, C., Boucher, M., Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. Int. Clin. Psychopharmacol. 29 (2014), 239–251.
51. Larson, J.S., The MOS 36-item short form health survey. A conceptual analysis. Eval. Health Prof. 20 (1997), 14–27.
52. Leinonen, E., Skarstein, J., Behnke, K., Agren, H., Helsdingen, J.T., Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nord. Antidepressant Study Group. Int. Clin. Psychopharmacol. 14 (1999), 329–337.
53. Leon, A.C., Solomon, D.A., Mueller, T.I., Turvey, C.L., Endicott, J., Keller, M.B., The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment. Psychol. Med. 29 (1999), 869–878.
54. Levinson, D., Lakoma, M.D., Petukhova, M., Schoenbaum, M., Zaslavsky, A.M., Angermeyer, M., Borges, G., Bruffaerts, R., G., dG., R., dG., Gureje, O., Haro, J.M., Hu, C., Karam, A.N., Kawakami, N., Lee, S., Lepine, J.P., Browne, M.O., Okoliyski, M., Posada-Villa, J., Sagar, R., Viana, M.C., Williams, D.R., Kessler, R.C., Associations of serious mental illness with earnings: results from the WHO World Mental Health Surveys. Br. J. Psychiatry 197 (2010), 114–121.
55. Lim, L., Jin, A.Z., Ng, T.P., Anxiety and depression, chronic physical conditions, and quality of life in an urban population sample study. Soc. Psychiatry Psychiatr. Epidemiol. 47 (2012), 1047–1053.
56. Lydiard, R.B., Stahl, S.M., Hertzman, M., Harrison, W.M., A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J. Clin. Psychiatry 58 (1997), 484–491.
57. Mahableshwarkar, A.R., Zajecka, J., Jacobson, W., Chen, Y., Keefe, R.S., A randomized, placebo-controlled, active-reference, Double-blind, flexible-dose study of the Efficacy of Vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 40 (2015), 2025–2037.
58. Mancini, M., Sheehan, D.V., Demyttenaere, K., Amore, M., Deberdt, W., Quail, D., Sagman, D., Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. Int. Clin. Psychopharmacol. 27 (2012), 298–309.
59. Martinez, J.M., Katon, W., Greist, J.H., Kroenke, K., Thase, M.E., Meyers, A.L., Edwards, S.E., Marangell, L.B., Shoemaker, S., Swindle, R., A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int. Clin. Psychopharmacol. 27 (2012), 17–26.
60. McIntyre, R.S., Schaffer, A., Beaulieu, S., The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid conditions. Ann. Clin. Psychiatry 24 (2012), 2–3.
61. McIntyre, R.S., Lophaven, S., Olsen, C.K., A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol., 2014, 1–11.
62. Menear, M., Dore, I., Cloutier, A.M., Perrier, L., Roberge, P., Duhoux, A., Houle, J., Fournier, L., The influence of comorbid chronic physical conditions on depression recognition in primary care: a systematic review. J. Psychosom. Res 78 (2015), 304–313.
63. Miller, I.W., Keitner, G.I., Schatzberg, A.F., Klein, D.N., Thase, M.E., Rush, A.J., Markowitz, J.C., Schlager, D.S., Kornstein, S.G., Davis, S.M., Harrison, W.M., Keller, M.B., The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J. Clin. Psychiatry 59 (1998), 608–619.
64. Molenaar, P.J., Dekker, J., Van, R., Hendriksen, M., Vink, A., Schoevers, R.A., Does adding psychotherapy to pharmacotherapy improve social functioning in the treatment of outpatient depression?. Depress Anxiety 24 (2007), 553–562.
65. Montgomery, S.A., Mansuy, L., Ruth, A., Bose, A., Li, H., Li, D., Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J. Clin. Psychiatry 74 (2013), 363–369.
66. Montgomery, S.A., Mansuy, L., Ruth, A.C., Li, D., Gommoll, C., The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 29 (2014), 26–35.
67. Mundt, J.C., Marks, I.M., Shear, M.K., Greist, J.H., The work and social adjustment scale: a simple measure of impairment in functioning. Br. J. Psychiatry 180 (2002), 461–464.
68. Oakes, T.M., Myers, A.L., Marangell, L.B., Ahl, J., Prakash, A., Thase, M.E., Kornstein, S.G., Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol. Hum. Psychopharmacol. 27 (2012), 47–56.
69. Papakostas, G.I., Petersen, T., Denninger, J.W., Tossani, E., Pava, J.A., Alpert, J.E., Nierenberg, A.A., Fava, M., Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J. Clin. Psychopharmacol. 24 (2004), 507–511.
70. Papakostas, G.I., Nelson, J.C., Kasper, S., Moller, H.J., A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur. Neuropsychopharmacol. 18 (2008), 122–127.
71. Papakostas, G.I., Culpepper, L., Fayyad, R.S., Musgnung, J., Guico-Pabia, C.J., Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of 6 randomized, double-blind, placebo-controlled studies. Int. Clin. Psychopharmacol. 28 (2013), 312–321.
72. Pu, S., Matsumura, H., Yamada, T., Ikezawa, S., Mitani, H., Adachi, A., Nakagome, K., Reduced frontopolar activation during verbal fluency task associated with poor social functioning in late-onset major depression: multi-channel near-infrared spectroscopy study. Psychiatry Clin. Neurosci. 62 (2008), 728–737.
73. Pu, S., Yamada, T., Yokoyama, K., Matsumura, H., Mitani, H., Adachi, A., Kaneko, K., Nakagome, K., Reduced prefrontal cortex activation during the working memory task associated with poor social functioning in late-onset depression: multi-channel near-infrared spectroscopy study. Psychiatry Res. 203 (2012), 222–228.
74. Rabin, R., de Charro, F., EQ-5D: a measure of health status from the EuroQol Group 16. Ann. Med. 33 (2001), 337–343.
75. Rapaport, M.H., Clary, C., Fayyad, R., Endicott, J., Quality-of-life impairment in depressive and anxiety disorders. Am. J. Psychiatry 162 (2005), 1171–1178.
76. Raskin, J., Wiltse, C.G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J.J., Rotz, B.T., Mohs, R.C., Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 164 (2007), 900–909.
77. Reddy, S., Fayyad, R., Edgar, C.J., Guico-Pabia, C.J., Wesnes, K., The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebl-controlled trial. J. Psychopharmacol., 30, 2016, 559.
78. Reilly, M.C., Zbrozek, A.S., Dukes, E.M., The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4 (1993), 353–365.
79. Robinson, M.J., Sheehan, D., Gaynor, P.J., Marangell, L.B., Tanaka, Y., Lipsius, S., Ohara, F., Namiki, C., Relationship between major depressive disorder and associated painful physical symptoms: analysis of data from two pooled placebo-controlled, randomized studies of duloxetine. Int. Clin. Psychopharmacol. 28 (2013), 330–338.
80. Rock, P.L., Roiser, J.P., Riedel, W.J., Blackwell, A.D., Cognitive impairment in depression: a systematic review and meta-analysis. Psychol. Med. 44 (2014), 2029–2040.
81. Rost, K., Smith, J.L., Dickinson, M., The effect of improving primary care depression management on employee absenteeism and productivity. Random. Trial Med. Care 42 (2004), 1202–1210.
82. Rush, A.J., Distinguishing functional from syndromal recovery: implications for clinical care and research. J. Clin. Psychiatry 76 (2015), e832–e834.
83. Sambunaris, A., Bose, A., Gommoll, C.P., Chen, C., Greenberg, W.M., Sheehan, D.V., A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J. Clin. Psychopharmacol. 34 (2014), 47–56.
84. Sambunaris, A., Gommoll, C., Chen, C., Greenberg, W.M., Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int. Clin. Psychopharmacol. 29 (2014), 197–205.
85. Sheehan, D.V., Harnett-Sheehan, K., Raj, B.A., The measurement of disability. Int. Clin. Psychopharmacol. 11:Suppl 3 (1996), S89–S95.
86. Sheehan, D.V., Harnett-Sheehan, K., Spann, M.E., Thompson, H.F., Prakash, A., Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. Int. Clin. Psychopharmacol. 26 (2011), 75–83.
87. Sheehan, K.H., Sheehan, D.V., Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale. Int. Clin. Psychopharmacol. 23 (2008), 70–83.
88. Shippee, N.D., Shah, N.D., Williams, M.D., Moriarty, J.P., Frye, M.A., Ziegenfuss, J.Y., Differences in demographic composition and in work, social, and functional limitations among the populations with unipolar depression and bipolar disorder: results from a nationally representative sample. Health Qual. Life Outcomes, 9, 2011, 90.
89. Simon, G.E., VonKorff, M., Heiligenstein, J.H., Revicki, D.A., Grothaus, L., Katon, W., Wagner, E.H., Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 275 (1996), 1897–1902.
90. Soares, C.N., Kornstein, S.G., Thase, M.E., Jiang, Q., Guico-Pabia, C.J., Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J. Clin. Psychiatry 70 (2009), 1365–1371.
91. Soares, C.N., Endicott, J., Boucher, M., Fayyad, R.S., Guico-Pabia, C.J., Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder. CNS Spectr. 19 (2014), 519–527.
92. Solomon, D.A., Leon, A.C., Coryell, W., Mueller, T.I., Posternak, M., Endicott, J., Keller, M.B., Predicting recovery from episodes of major depression. J. Affect. Disord 107 (2008), 285–291.
93. Startup, M., Jackson, M.C., Bendix, S., The concurrent validity of the Global assessment of functioning (GAF). Br. J. Clin. Psychol. 41 (2002), 417–422.
94. Stewart, W.F., Ricci, J.A., Chee, E., Hahn, S.R., Morganstein, D., Cost of lost productive work time among US workers with depression. JAMA 289 (2003), 3135–3144.
95. Targum, S.D., Wedel, P.C., Fava, M., Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder. J. Psychiatr. Res. 68 (2015), 392–396.
96. Thase, M.E., Unmet needs in the management of major depressive disorder. CNS Spectr. 15 (2010), 4–7.
97. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs, M.M., Balasubramani, G.K., Fava, M., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163 (2006), 28–40.
98. Trivedi, M.H., Corey-Lisle, P.K., Guo, Z., Lennox, R.D., Pikalov, A., Kim, E., Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int. Clin. Psychopharmacol. 24 (2009), 133–138.
99. Trivedi, M.H., Dunner, D.L., Kornstein, S.G., Thase, M.E., Zajecka, J.M., Rothschild, A.J., Friedman, E.S., Shelton, R.C., Keller, M.B., Kocsis, J.H., Gelenberg, A., Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J. Affect. Disord. 126 (2010), 420–429.
100. Trivedi, M.H., Morris, D.W., Wisniewski, S.R., Lesser, I., Nierenberg, A.A., Daly, E., Kurian, B.T., Gaynes, B.N., Balasubramani, G.K., Rush, A.J., Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am. J. Psychiatry 170 (2013), 633–641.
101. Versiani, M., Moreno, R., Ramakers-van Moorsel, C.J., Schutte, A.J., Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 19 (2005), 137–146.
102. van der Voort, T.Y., Seldenrijk, A., van, M.B., Goossens, P.J., Beekman, A.T., Penninx, B.W., Kupka, R.W., Functional versus syndromal recovery in patients with major depressive disorder and bipolar disorder. J. Clin. Psychiatry 76 (2015), e809–e814.
103. Wada, K., Arakida, M., Watanabe, R., Negishi, M., Sato, J., Tsutsumi, A., The economic impact of loss of performance due to absenteeism and presenteeism caused by depressive symptoms and comorbid health conditions among Japanese workers. Ind. Health 51 (2013), 482–489.
104. Wang, P.S., Simon, G.E., Avorn, J., Azocar, F., Ludman, E.J., McCulloch, J., Petukhova, M.Z., Kessler, R.C., Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. JAMA 298 (2007), 1401–1411.
105. Wells, K.B., Stewart, A., Hays, R.D., Burnam, M.A., Rogers, W., Daniels, M., Berry, S., Greenfield, S., Ware, J., The functioning and well-being of depressed patients. results from the Medical Outcomes Study. JAMA 262 (1989), 914–919.
106. Wheatley, D.P., van, M.M., Timmerman, L., Kremer, C.M., Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J. Clin. Psychiatry 59 (1998), 306–312.
107. Wise, T.N., Meyers, A.L., Desaiah, D., Mallinckrodt, C.H., Robinson, M.J., Kajdasz, D.K., The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials. Prim. Care Companion J. Clin. Psychiatry 10 (2008), 270–275.
108. World Health Organization, 2012. Depression. Fact sheet 369. Available at: http://www.who.int/mediacentre/factsheets/fs369/en/ (Accessed 11.06.15).
109. World Health Organization, WHO-5 Well-Being Index. 1998, World Health Organization, Hilleroed, Denmark.
110. World Health Organization 2008. The global burden of disease. 2004 update. Available at: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html (Accessed 11.06.15).
111. World Health Organization, WHODAS 2.0: World Health Organization Disability Assessment Schedule 2.0. 2014, World Health Organization/National Institutes of Health, Geneva, Switzerland.
112. Zimmerman, M., McGlinchey, J.B., Posternak, M.A., Friedman, M., Attiullah, N., Boerescu, D., How should remission from depression be defined? The depressed patient's perspective. Am. J. Psychiatry 163 (2006), 148–150.
113. Zu, S., Xiang, Y.T., Liu, J., Zhang, L., Wang, G., Ma, X., Kilbourne, A.M., Ungvari, G.S., Chiu, H.F., Lai, K.Y., Wong, S.Y., Yu, D.S., Li, Z.J., A comparison of cognitive-behavioral therapy, antidepressants, their combination and standard treatment for Chinese patients with moderate-severe major depressive disorders. J. Affect. Disord. 152–154 (2014), 262–267.